1. Home
  2. BTAI vs REFR Comparison

BTAI vs REFR Comparison

Compare BTAI & REFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

N/A

Current Price

$1.25

Market Cap

34.9M

Sector

Health Care

ML Signal

N/A

Logo Research Frontiers Incorporated

REFR

Research Frontiers Incorporated

N/A

Current Price

$0.78

Market Cap

30.2M

Sector

Miscellaneous

ML Signal

N/A

Company Overview

Basic Information
Metric
BTAI
REFR
Founded
2017
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Multi-Sector Companies
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
34.9M
30.2M
IPO Year
2018
1995

Fundamental Metrics

Financial Performance
Metric
BTAI
REFR
Price
$1.25
$0.78
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$23.00
N/A
AVG Volume (30 Days)
597.0K
29.4K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
75.63
N/A
EPS
N/A
N/A
Revenue
N/A
$1,488,642.00
Revenue This Year
$197.82
N/A
Revenue Next Year
$910.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.01
$0.73
52 Week High
$8.08
$2.70

Technical Indicators

Market Signals
Indicator
BTAI
REFR
Relative Strength Index (RSI) 53.70 44.11
Support Level $1.05 $0.75
Resistance Level $1.26 $1.02
Average True Range (ATR) 0.08 0.04
MACD 0.01 0.01
Stochastic Oscillator 47.83 45.22

Price Performance

Historical Comparison
BTAI
REFR

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

About REFR Research Frontiers Incorporated

Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.

Share on Social Networks: